Anti-CD22-CAR T cell therapy (Kecellitics Biotech)

N/A

Report date: 2024/01/05 13:47:37

Base Information

Drug NameAnti-CD22-CAR T cell therapy (Kecellitics Biotech)
Drug Alias NameAnti-CD22 chimeric antigen receptor T cell therapy (Kecellitics Biotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD22
TargetsCD22
Therapy Area/IndicationsLymphoma, B-CellLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKecellitics Biotech Company Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKecellitics Biotech Company Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A